CLINICAL STUDIES OF ACTINOMYCIN D WITH SPECIAL REFERENCE TO WILMS' TUMOR IN CHILDREN *
S. Farber,G. D'angio,A. Evans,A. Mitus
DOI: https://doi.org/10.1111/J.1749-6632.1960.TB20165.X
1960-10-01
Abstract:This publication commemorates the 20th anniversary of the discovery of actinomycins by Selman A. Waksman. The vast importance of products of the actinomyces in the treatment of infectious disease is now a part of medical history. Twelve years after the isolation of actinomycin by Waksman and Woodruff in 1940,’ Hackmann* in 1952 demonstrated the carcinolytic effect of actinomycin C. Studies made by Ravina and others in 19543 pointed clearly to the possible usefulness of this substance in the treatment of some forms of cancer in man, such as Hodgkin’s disease. The studies summarized in this paper had their origin in discussions with Waksman in 1954. The antibiotic selected for initial study, actinomycin D, very quickly proved to be, on the basis of weight, the most powerful anticancer agent against transplanted tumors in the mouse that we had studied up to that time.4t5 Clinical studies, begun as soon as extensive toxicological studies were completed, demonstrated no value in the treatment of acute leukemia in children. When administered to children with advanced Wilms’ tumor, rhabdomyosarcoma, Ewing’s tumor, and Hodgkin’s disease, however, there was sufficient evidence of clinical improvement to warrant trials against many different kinds of cancer in man.6 Our clinical studies, conducted over the past five years, include observations of 330 patients having many different forms of disseminated or advanced cancer. These studies form the background for the opinions expressed here, although discussion will be limited to observations made on children with Wilms’ tumor of the kidney. Actinomycin D was injected intravenously, with special precautions taken. Since local necrosis is caused, if extravasation occurs, it was never administered directly with syringe and needle. I t is administered best into the side arm as an intravenous infusion or by means of a commercially available scalp-vein set. In our earlier studies, the dose administered was 75 pg./kg. for a total course when combined with X-ray therapy, and 100 pg./kg. per course when given alone. During the past two years we have employed a somewhat lower dose, which has been better tolerated, and are now using 60 pg./kg. combined with X-ray therapy or 75 pg./kg. alone. The dose schedules should be selected for the individual patient, and treatment should be stopped if any signs of important degrees of toxicity are recognized. Single injections vary from 100 to 400 pg., and the course usually lasts seven to fourteen days. Actinomycin D causes depression of the bone marrow, thrombocytopenia being the first indication of toxicity. Therapy is interrupted if the level of platelets falls below 15O,OOO/cu. mm. Evidences of toxicity, such as stomatitis and gastrointestinal